Hepion Pharmaceuticals Net Worth
Hepion Pharmaceuticals Net Worth Breakdown | HEPA |
Hepion Pharmaceuticals Net Worth Analysis
Hepion Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Hepion Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Hepion Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Hepion Pharmaceuticals' net worth analysis. One common approach is to calculate Hepion Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Hepion Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Hepion Pharmaceuticals' net worth. This approach calculates the present value of Hepion Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Hepion Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Hepion Pharmaceuticals' net worth. This involves comparing Hepion Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Hepion Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Hepion Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Hepion Pharmaceuticals' net worth research are outlined below:
| Hepion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Hepion Pharmaceuticals has high historical volatility and very poor performance | |
| Hepion Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Hepion Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (48.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hepion Pharmaceuticals currently holds about 59.15 M in cash with (40.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hepion Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Tuesdays Pre-Market Session - Benzinga |
Hepion Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Hepion Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hepion Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Hepion Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hepion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hepion Pharmaceuticals backward and forwards among themselves. Hepion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Hepion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 175 | Advisor Group Holdings, Inc. | 2024-09-30 | 113 | Group One Trading, Lp | 2024-09-30 | 84.0 | Advisornet Financial, Inc | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-09-30 | 48.0 | Barclays Plc | 2024-09-30 | 16.0 | Ubs Group Ag | 2024-09-30 | 3.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Global Retirement Partners, Llc. | 2024-09-30 | 1.0 | Anson Funds Management Lp | 2024-09-30 | 231.8 K | Vanguard Group Inc | 2024-09-30 | 90.9 K |
Follow Hepion Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.98 M.Market Cap |
|
Project Hepion Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.43) | (2.56) | |
| Return On Capital Employed | (4.35) | (4.13) | |
| Return On Assets | (2.43) | (2.56) | |
| Return On Equity | (6.05) | (5.75) |
When accessing Hepion Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Hepion Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Hepion Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Hepion Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Hepion Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Hepion Pharmaceuticals' management manipulating its earnings.
Evaluate Hepion Pharmaceuticals' management efficiency
Hepion Pharmaceuticals has return on total asset (ROA) of (0.9282) % which means that it has lost $0.9282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -2.56. The current year's Return On Capital Employed is expected to grow to -4.13. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 23.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 243 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.65 | 1.57 | |
| Tangible Book Value Per Share | 1.65 | 1.73 | |
| Enterprise Value Over EBITDA | 0.03 | 0.03 | |
| Price Book Value Ratio | 1.59 | 1.67 | |
| Enterprise Value Multiple | 0.03 | 0.03 | |
| Price Fair Value | 1.59 | 1.67 | |
| Enterprise Value | -2 M | -2.1 M |
Effective leadership at Hepion Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hepion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hepion Pharmaceuticals time-series forecasting models is one of many Hepion Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hepion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Hepion Pharmaceuticals Earnings per Share Projection vs Actual
Hepion Pharmaceuticals Corporate Management
| BSc BSc | CEO Pres | Profile | |
| Patrick Mayo | Senior Pharmacology | Profile | |
| John Cavan | Chief Officer | Profile | |
| Sharen Pyatetskaya | Director Relations | Profile | |
| Todd MD | Chief Officer | Profile | |
| Daniel Trepanier | Senior Development | Profile | |
| Daren Ure | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.